Sign In
Last checked at 
5 Mar 2026 16:19
05 March 2026
ECO Animal Health Group plc
("ECO" or the "Company")
Block Listing Return
ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health company with a portfolio of marketed veterinary products and a maturing proprietary R&D pipeline, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:
Name of applicant: | ECO Animal Health Group plc | |||
Name of scheme: | Executive Share Option Scheme and Unapproved Share Option Scheme | |||
Number and class of securities originally listed and the date of admission: | 1,500,000 ordinary shares of 5 pence each on 20 July 2017 | |||
Period of return: | From: | 12 August 2025 | To: | 12 February 2026 |
Balance of unallotted securities under scheme(s) from previous return: | 375,505 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
Less: Number of securities issued/allotted under scheme(s) during period: | 0 | |||
Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 375,505 | |||
-Ends-
Contacts
ECO Animal Health Group plc David Hallas (Chief Executive Officer) Christopher Wilks (Chief Financial Officer)
| 020 8447 8899 |
ICR Healthcare (Financial PR) Mary-Jane Elliott Jessica Hodgson
| 020 3709 5700
|
Singer Capital Markets (Nominated Adviser & Joint Broker) Philip Davies Jalini Kalaravy Samed Ethemi
| 020 7496 3000 |
Panmure Liberum (Joint Broker) Emma Earl Will Goode Mark Rogers Rupert Dearden
| 020 3100 2000 |
Equity Development Hannah Crowe Matt Evans | 020 7065 2692 |
About ECO Animal Health
ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.
Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.
Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.
Click here for more information: https://ecoanimalhealth.com
Follow the stocks
